Ever Supreme Bio Technology Co., Ltd (TPEX:6712)

Taiwan · Delayed Price · Currency is TWD

139.00

+1.00 (0.72%)

Jun 18, 2026, 1:30 PM CST

-6.14% (1Y)

Market Cap	14.15B +4.2%
Revenue (ttm)	1.03B +8.6%
Net Income	473.03M +9.1%
EPS	5.03 -2.0%
Shares Out	101.77M
PE Ratio	27.64
Forward PE	31.12
Dividend	3.33 (2.40%)
Ex-Dividend Date	Apr 16, 2026

Volume	221,893
Open	139.50
Previous Close	138.00
Day's Range	138.00 - 139.50
52-Week Range	120.95 - 179.05
Beta	0.44
Analysts	Strong Buy
Price Target	200.00 (+43.89%)
Earnings Date	Aug 10, 2026

About TPEX:6712

Ever Supreme Bio Technology Co., Ltd engages in the research, development, and manufacture of drug products related to human mesenchymal stem cells and immune cells in Taiwan. The company operates through two segments: Cell Preparation Business and Other Operating Business segments. The company’s products include umbilical cord mesenchymal stem cells, a drug candidate in Phase I clinical trials for the treatment of myocardial infarction and stroke. It also develops dendritic cell vaccine, a drug candidate in Phase II clinical trials for the tre... [Read more]

Industry Biotechnology

Sector Healthcare

Founded 2016

Employees 94

Stock Exchange Taipei Exchange

Ticker Symbol 6712

Full Company Profile

Financial Performance

In 2025, TPEX:6712's revenue was 1.02 billion, an increase of 8.96% compared to the previous year's 933.81 million. Earnings were 429.43 million, an increase of 16.93%.

Financial Statements